SEC Form 4 · accession 0001708138-18-000006
REGENERON PHARMACEUTICALS, INC. · REGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
George L Sing
Director
Period of report
May 9, 2018
Accepted (ET)
May 11, 2018 · 4:02 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000872589
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | May 9, 2018 | S | 7,000 | $285.29 | D | 127,772 | D | |
| Common Stock | May 10, 2018 | S | 3,000 | $285.00 | D | 124,772 | D | |
| Common Stock | May 10, 2018 | S | 3,000 | $286.00 | D | 121,772 | D | |
| Common Stock | May 10, 2018 | S | 3,000 | $287.00 | D | 118,772 | D | |
| Common Stock | May 10, 2018 | S | 4,000 | $288.00 | D | 114,772 | D | |
| Common Stock | holding | — | — | — | 3,000 | I | by Spouse | |
| Common Stock | holding | — | — | — | 4,500 | I | by Spouse/Cust Son | |
| Common Stock | holding | — | — | — | 10,000 | I | by Trust for Son |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents volume-weighted average price of sales of 7,000 shares of Company stock on May 9, 2018 at prices ranging from $285.00 to $285.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 9, 2018 at each separate price.